Access to healthcare remains a challenge, with limited availability of routine blood testing globally. Truvian Health aims to solve this issue through its innovative platform, enabling high-quality blood tests anywhere.
Truvian recently secured $74 million to support its FDA clearance efforts. The platform offers a convenient solution to the complex and time-consuming nature of traditional blood testing, which has led to missed diagnoses and unnecessary healthcare costs.
Truvian’s benchtop platform empowers clinics, doctors’ offices, and pharmacies to perform comprehensive, accurate blood tests with results comparable to those of central laboratories. Multiple clinical studies have demonstrated the equivalence of its platform’s results to those of central labs across a wide range of tests.
Key investors in this funding round include Wittington Ventures and Great Point Ventures, alongside continued support from existing partners. Shoppers Drug Mart, Canada’s largest pharmacy, has joined Truvian as a commercial partner, showcasing the platform’s potential.
Shoppers Drug Mart conducted an on-site evaluation, comparing results from Truvian’s platform to a central laboratory. The highly concordant results highlighted the platform’s potential to revolutionize healthcare.
Truvian’s platform has been extensively tested and has demonstrated a high-reliability rate, with over 50,000 samples analyzed and a single-sample approach that covers a comprehensive panel of tests. The company is expanding its manufacturing capabilities to support clinical trials and early partner access programs.
Truvian’s platform represents a significant advancement in healthcare, providing convenient, high-quality blood testing to improve patient outcomes and reduce healthcare system costs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
